Journal
CANCER SCIENCE
Volume 108, Issue 5, Pages 886-896Publisher
WILEY
DOI: 10.1111/cas.13210
Keywords
Biomarker; miR-135a-3p; molecular target; nucleic acid therapy; ovarian cancer
Categories
Funding
- Central Research Institute of Fukuoka University [141011]
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Kakihara Science and Technology Foundation
- Princess Takamatsu Cancer Research Fund
- [227790536]
- [26670731]
- [23592470]
- [26293362]
Ask authors/readers for more resources
Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT-PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR-135a-3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available